Matinas BioPharma Holdings, Inc.
MTNB · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.00 | 0.00 | -0.00 |
| FCF Yield | -14.35% | -44.64% | -75.87% | -141.44% |
| EV / EBITDA | -4.55 | -0.29 | 1.02 | 0.50 |
| Quality | ||||
| ROIC | -17.42% | -16.28% | -18.40% | -37.24% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.96 | 0.39 | 1.21 | 0.42 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 27.07% | -0.70% | 42.82% | -0.29% |
| Safety | ||||
| Net Debt / EBITDA | 1.97 | 2.17 | 2.76 | 1.16 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -121.21 | -198.28 | -17.78 |